By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…
By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…
Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…
London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…
In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…
Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…
Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…
Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…
BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…
In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…
Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…
On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…
President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…
Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…
Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…
Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…
Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.
New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…
Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…
International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…
By Alexandros Soumalevris, GPI Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…
By Preeti Patel Finding the right price in a cost-constrained global healthcare environment Needless to reiterate that costs of healthcare continue to increase. Some of the main drivers behind this trend are the development costs of novel and efficacious medicines which have the…
